Jounce Therapeutics (NASDAQ:JNCE) Issues Quarterly Earnings Results

Jounce Therapeutics (NASDAQ:JNCE) issued its earnings results on Thursday. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.24 by $0.66, Fidelity Earnings reports. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The business had revenue of $119.45 million for the quarter, compared to the consensus estimate of $99.97 million.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Shares of JNCE stock traded up $0.06 on Friday, reaching $4.06. The stock had a trading volume of 211,300 shares, compared to its average volume of 175,348. Jounce Therapeutics has a 1 year low of $2.66 and a 1 year high of $7.35. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.03 and a current ratio of 2.03. The company has a 50 day simple moving average of $3.49 and a 200 day simple moving average of $4.28. The stock has a market cap of $124.67 million, a P/E ratio of -4.83 and a beta of 3.51.

A number of research firms have recently issued reports on JNCE. JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a research note on Sunday, August 11th. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Saturday. Finally, ValuEngine downgraded Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 29th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $8.75.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Further Reading: What does the Dogs of the Dow mean?

Earnings History for Jounce Therapeutics (NASDAQ:JNCE)

Leave a Reply

Your email address will not be published. Required fields are marked *

*